Neurocognitive moderation of repetitive transcranial magnetic stimulation (rTMS) effects on cannabis use in schizophrenia: a preliminary analysis

Samantha Johnstone1,7, Darby J. E. Lowe1,7, Karolina Kozak-Bidzinski1, Marcos Sanches1, David J. Castle1,2, Jennifer S. Rabin3,4,5, Rachel A. Rabin6 and Tony P. George1,2✉

Repetitive transcranial magnetic stimulation (rTMS) is a promising treatment for cannabis use disorder in schizophrenia; however, gaps in the literature remain as to the potential role of neurocognitive functioning in treatment response. We evaluated the moderating role of select cognitive functions including baseline executive functioning, verbal memory, and sustained attention, and we explore the mediating role of changes in task performance on changes in cannabis use in both active and sham rTMS groups. Participants underwent high-frequency (20 Hz) rTMS applied to the bilateral dorsolateral prefrontal cortex 5x/week for 4 weeks. Weekly self-report of cannabis use and semi-quantitative urinary carboxy-tetrahydrocannabinol levels were recorded. A neurocognitive battery assessing verbal memory, visuospatial working memory, verbal working memory, sustained attention, delayed discounting, and complex planning was administered pre- and post-treatment. Better baseline performance on tasks assessing sustained attention, delayed discounting, and complex planning moderated the extent to which participants in the active group reduced cannabis use. There were no significant indirect pathways between treatment, changes in neuropsychological performance, and changes in cannabis use; however, active rTMS improved complex planning and sustained attention. These preliminary findings suggest that there is a moderating role of sustained attention, delayed discounting, and complex planning on the effects of rTMS on cannabis use. Further, mediation models suggest rTMS may exert direct effects on cannabis use independent of its effects on cognitive functioning in people with SCZ. Trial Registration: clinicaltrials.gov: NCT03189810.

Schizophrenia (2022);8:99; https://doi.org/10.1038/s41537-022-00303-2

INTRODUCTION

Schizophrenia (SCZ) is a chronic psychotic disorder associated with significant impairment in a wide range of cognitive functions, including executive function. The latter is manifested clinically by deficits in attaining goals, solving complex problems, memory and attention1. SCZ is highly comorbid with cannabis use disorder (CUD) with a prevalence of ~26%6, and linked to poorer clinical and cognitive outcomes3. Executive dysfunction in SCZ impairs patient engagement with psychological and pharmacological treatments and impairs recovery attempts.

Amongst people with substance use disorders, cognitive functioning predicts several indicators of successful addiction recovery. For example, better performance on executive function and verbal memory tasks (which is strongly related to executive functioning capacity4) predict greater motivation for changes in substance use behavior7, whereas poorer performance predicts greater denial in the need for substance use change8. Similarly, sustained attention predicts motivation for substance use behavior change9. In addition, intact executive function has been correlated with recovery-based self-efficacy and participation in therapy for substance use10. Furthermore, poorer delayed discounting and inability to delay gratification or control impulses were related to reduced capacity to learn effective coping skills for substance use11, whereas deficits in working memory predict substance use relapse after treatment12. As such, preserved cognitive functioning, particularly in aspects of executive function may play a role in addiction treatment response13.

There is extensive overlapping neurobiology of SCZ and CUD, including dysregulated gamma aminobutyric acid activity (GABA), and catechol-O-methyltransferase (COMT) allelic gene variation, and dysfunctional endocannabinoid system, particularly a greater density of cannabinoid receptor type 1 (CB1Rs) in the dorsolateral prefrontal cortex (DLPFC14), which contributes to dysregulated reward system functioning in addiction15. Repetitive transcranial magnetic stimulation (rTMS) represents a promising treatment that may target CUD while bypassing cognition-related difficulties in treatment engagement for SCZ patients16 and has dual potential as an intervention for both disorders17–19. In comorbid CUD and SCZ, rTMS applied to the DLPFC may regulate subcortical activity (e.g., glutamatergic, GABAergic, and dopaminergic neurotransmission in the mesolimbic pathway), as is seen in addiction without SCZ20,21. Regulation of subcortical activity may directly reduce cravings for cannabis as well as improve top-down cognitive control processes, and thus inhibition of craving and consumption of substances17.

In a case-series with non-psychiatric participants with CUD, rTMS showed efficacy in reducing cravings for cannabis and amount of cannabis used weekly22, although evidence with respect to changes in cannabis cravings is mixed23. Furthermore,
| Neuropsychological measure | Fixed effects                      | Estimate | SE    | df  | t     | p     |
|---------------------------|-----------------------------------|----------|-------|-----|-------|-------|
| NarcoCheck (ng/mL)        | Intercept                         | 343.89   | 50.13 | 18.13 | 6.86  | <0.001*** |
|                           | Treatment                         | −14.72   | 50.13 | 18.13 | −0.29 | 0.77  |
|                           | Time                              | **54.03**| **21.03**| **16.70**| **2.57**| **0.020*** |
|                           | HVLT-R                            | −33.40   | 51.60 | 35.82 | −0.65 | 0.52  |
|                           | Treatment x Time                  | 31.40    | 21.03 | 16.70 | 1.49  | 0.15  |
|                           | Treatment x HVLT-R                | −88.43   | 51.60 | 35.82 | −1.71 | 0.095 |
|                           | Time x HVLT-R                     | −24.01   | 30.56 | 18.24 | −0.79 | 0.44  |
|                           | Treatment x Time x HVLT-R         | −28.54   | 30.56 | 18.24 | −0.93 | 0.36  |
| SDR composite             | Intercept                         | 348.11   | 48.98 | 18.80 | 7.11  | <0.001*** |
|                           | Treatment                         | −28.83   | 48.98 | 18.80 | 0.59  | 0.56  |
|                           | Time                              | **51.51**| **22.61**| **17.82**| **2.28**| **0.035*** |
|                           | SDR                               | 12.81    | 55.77 | 30.18 | 0.23  | 0.82  |
|                           | Treatment x Time                  | 38.52    | 22.61 | 17.82 | 1.70  | 0.11  |
|                           | Treatment x SDR                   | −18.63   | 55.77 | 30.18 | −0.33 | 0.74  |
|                           | Time x SDR                        | 41.02    | 39.40 | 18.24 | 1.04  | 0.31  |
|                           | Treatment x Time x SDR            | 63.47    | 39.40 | 18.24 | 1.61  | 0.12  |
| CPT attentional index     | Intercept                         | 375.15   | 40.05 | 14.94 | 9.37  | <0.001*** |
|                           | Treatment                         | 2.39     | 40.05 | 14.94 | 0.06  | 0.95  |
|                           | Time                              | 49.15    | 23.42 | 13.18 | 2.10  | 0.055 |
|                           | CPT                               | 42.21    | 21.93 | 23.50 | 1.92  | 0.066 |
|                           | Treatment x Time                  | 34.11    | 23.42 | 13.18 | 1.46  | 0.16  |
|                           | Treatment x CPT                   | **−69.87**| **21.93**| **23.50**| **−3.19**| **<0.01*** |
|                           | Time x CPT                        | −5.98    | 15.12 | 16.02 | −0.40 | 0.69  |
|                           | Treatment x Time x CPT            | −5.21    | 15.12 | 16.02 | −0.34 | 0.73  |
| CPT hit rate              | Intercept                         | 604.68   | 363.62| 32.85 | 1.66  | 0.11  |
|                           | Treatment                         | 106.31   | 363.62| 32.85 | 0.29  | 0.77  |
|                           | Time                              | 64.71    | 193.93| 18.04 | 0.33  | 0.74  |
|                           | CPT                               | −0.59    | 0.90  | 32.71 | −0.65 | 0.52  |
|                           | Treatment x Time                  | 94.30    | 193.93| 18.04 | 0.49  | 0.63  |
|                           | Treatment x CPT                   | −0.25    | 0.91  | 32.71 | −0.27 | 0.79  |
|                           | Time x CPT                        | −0.04    | 0.49  | 18.73 | −0.09 | 0.93  |
|                           | Treatment x Time x CPT            | −0.18    | 0.49  | 18.73 | −0.37 | 0.72  |
| DS forward                | Intercept                         | 892.16   | 126.93| 31.05 | 7.03  | <0.001*** |
|                           | Treatment                         | 45.56    | 126.93| 31.05 | 0.36  | 0.72  |
|                           | Time                              | −10.40   | 61.20 | 14.70 | −0.17 | 0.87  |
|                           | DS                                | −52.31   | 10.90 | 22.76 | −4.80 | <0.001*** |
|                           | Treatment x Time                  | **196.69**| **61.20**| **14.70**| **3.21**| **0.005*** |
|                           | Treatment x DS                    | −5.04    | 10.90 | 22.76 | −0.46 | 0.65  |
|                           | Time x DS                         | 4.67     | 5.76  | 14.61 | 0.81  | 0.43  |
|                           | Treatment x Time x DS             | −17.07   | 5.76  | 14.61 | −2.96 | **0.01*** |
| TOL total correct         | Intercept                         | 663.55   | 347.73| 11.71 | 1.91  | 0.08  |
|                           | Treatment                         | −185.48  | 347.73| 11.71 | −0.53 | 0.60  |
|                           | Time                              | 450.77   | 218.34| 8.63  | 2.07  | 0.07  |
|                           | TOL                               | −5.0     | 3.62  | 10.96 | −1.38 | 0.20  |
|                           | Treatment x Time                  | **−601.89**| **218.34**| **8.63**| **−2.76**| **0.023*** |
|                           | Treatment x TOL                   | 2.85     | 3.62  | 10.96 | 0.79  | 0.45  |
|                           | Time x TOL                        | −4.98    | 2.34  | 8.85  | −2.13 | 0.062 |
|                           | Treatment x Time x TOL            | **6.49** | **2.34**| **8.85**| **2.77**| **0.022*** |
| KDDT Geometric K          | Intercept                         | 256.04   | 101.30| 25.94 | 2.53  | 0.02  |
|                           | Treatment                         | **−297.53**| **101.30**| **25.94**| **−2.94**| **0.007*** |
|                           | Time                              | −13.33   | 72.86 | 13.85 | −0.18 | 0.85  |
|                           | Geo K                             | −15.64   | 21.23 | 14.54 | −0.74 | 0.47  |
in individuals with SCZ, our preliminary randomized controlled trial found trending treatment x time effects after 4 weeks of active versus sham treatment on cannabis use outcomes in people with SCZ. Specifically, there was a medium to large effect size in between-group differences in reduction of cannabis grams per day (GPD; $d = 0.72$) and a medium effect of tetrahydrocannabinol (THC) content in urine ($d = 0.55$) in the active group relative to the sham group. Furthermore, significant treatment x time interactions were found for improvements in the active group in cannabis craving, positive and general SCZ symptoms, depressive symptoms, and certain domains of cognition (e.g., sustained attention). Thus, rTMS may be a promising intervention for CUD in SCZ.

Due to gaps in the current literature, there are several questions that remain unanswered. (1) Are rTMS effects on reductions in cannabis use in SCZ dependent on better baseline cognitive functioning as is seen in behavioral and pharmacological treatment, and (2) Does rTMS improve neuropsychological performance and does this partially explain reductions in cannabis use? We conducted a secondary analysis of data from the rTMS treatment study in comorbid SCZ and CUD described above to assess the hypothesis that better baseline executive function, and in particular, delayed discounting and complex planning skills, results in greater cannabis reductions in the active rTMS group. Further, an exploratory analysis was conducted to ascertain hypothesized models of change. Specifically, we assess whether active rTMS induces changes in select cognitive functions that are hypothesized to be responsive to non-invasive neuromodulation, mediate the relationship between rTMS treatment and changes in cannabis use; namely, verbal memory, visuospatial working memory, verbal working memory, planning, and sustained attention.

RESULTS

Effect of baseline neuropsychological performance on cannabis outcomes

Delayed discounting. We found a significant interaction between treatment, time, and geometric K scores ($d = -0.62$, $[-1.19, -0.04]$), such that in the active group, smaller geometric K scores (i.e., better performance) predicted lower THC urinalysis content at the end of treatment (see Table 1), whereas in the sham group, smaller geometric K scores predicted greater THC urinalysis content at end of treatment. There was no three-way interaction with geometric K scores on GPD.

Complex planning. We observed a significant three-way interaction between treatment, time, and better accuracy performance on the TOL, such that in the active group, greater TOL total correct scores predicted reductions in GPD ($d = -1.86$, $[0.71, 2.97]$) and THC content in urinalysis ($d = -0.93$, $[0.13, 1.70]$) at the end of treatment, whereas this was not the case in the sham group (see Table 2). Conversely, longer problem-solving time on the TOL was associated with greater reductions in GPD ($d = 1.40$, $[0.37, 2.39]$) as was requiring more moves to complete the puzzle ($d = 1.04$, $[0.21, 1.84]$), constituting lower efficiency. Notably, participants with longer problem solving times had more correct towers ($r = 0.93$). There were no interaction effects of TOL initiation on GPD or THC content in urine.

Visuospatial working memory. We observed a trending interaction between treatment, time, and SDR composite scores ($d = -0.46$, $[-0.93, 0.03]$), such that in the active group, worse baseline SDR performance was associated with greater reductions in GPD. There were no significant interactions between treatment, time, and SDR scores on THC content in urine.

Verbal working memory. We found a significant interaction between treatment, time, and baseline performance on the Digit Span Forward task ($d = -0.77$, $[-1.35, -0.18]$), such that worse performance on the Digit Span Forward predicted greater reductions in THC content in urine from baseline to end of treatment in the active group. There were no interaction effects between treatment, time, and baseline performance on the Digit Span Backward task on THC content in urine nor the Digit Span task with time or treatment on GPD (Supplementary Table).

Sustained attention. Across both groups there was a trending moderation effect of better performance on CPT hit rate scores on reductions in GPD from baseline to end of treatment (time x CPT $d = -0.46$, $[-0.93, 0.03]$). Post hoc analyses showed higher CPT hit rate scores were related to greater reductions in GPD treatment in the active group ($d = 0.36$) as well as the sham group ($d = 0.39$). While there was no treatment x time interactions with CPT attentional index scores, we did observe a significant interaction between treatment and CPT attentional scores on GPD ($d = -0.54$, $[-0.94, -0.13]$) and THC content in urine ($d = -0.66$, $[-1.10, -0.21]$). Based on observation of the data (Supplementary Figure), reductions in cannabis use in the active group did not differ as a function of CPT attention index scores. There were no treatment x time interactions with CPT variability scores (Supplementary Table).

Memory. There were no significant interactions between treatment, time, and effects of baseline HVLT-R composite scores on cannabis GPD ($d = -0.23$, $[-0.67, 0.23]$) nor THC content in urine ($d = -0.22$, $[-0.68, 0.25]$).

Models of change analysis

To explore predicted models of change, we analyzed the mean change for the tasks hypothesized to change from baseline to Day 28 (see Fig. 1), for both the active and sham treatment groups as a mediator between treatment group and reductions in GPD. In the models of change, there was a small to medium effect of treatment group on improvements in HVLT-R percent retention ($a = 0.29$, $[-0.23, 0.82]$), discrimination index ($a = 0.27$, $[-0.79, 0.26]$), CPT attentional index ($a = 0.25$, $[-0.30, 0.80]$), and a medium effect in improvements in TOL time to initiation

---

**Table 1 continued**

| Neuropsychological measure | Fixed effects | Estimate | SE | df | t | p |
|----------------------------|--------------|---------|----|----|---|---|
| Treatment x Time           | -134.64      | 72.85   | 13.85 | -1.85 | 0.08 |
| Treatment x Geo K          | -80.39       | 21.23   | 14.54 | -3.79 | 0.001** |
| Time x Geo K               | -9.54        | 18.29   | 13.83 | -0.52 | 0.61 |
| Treatment x Time x Geo K   | -42.20       | 18.29   | 13.83 | -2.31 | 0.037* |

Hopkins Verbal Learning Test (HVLT-R), the Spatial Delayed Response (SDR), Continuous Performance Test (CPT), Digit Span (DS), Tower of London (TOL), Kirby Delay-Discounting Task (KDDT).

Bold values in the table represent significant interactions of interest ($p < 0.05$)

* $p < 0.05$; ** $p < 0.01$; *** $p < 0.001$
Table 2. Results of linear mixed-effects models fit with treatment, time, and baseline neuropsychological performance on cannabis grams per day.

| Neuropsychological measure | Fixed effects | Estimate | SE  | df  | t     | p  |
|----------------------------|---------------|----------|-----|-----|-------|----|
| **Grams per day**          |               |          |     |     |       |    |
|  | Intercept        | 0.60       | 0.09  | 18.08 | 6.61  | 0.000*** |
|  | Treatment        | −0.97      | 0.09  | 18.08 | −1.06 | 0.30  |
|  | Time             | **0.18**   | **0.05** | **17.06** | **3.43** | **0.003**** |
|  | HVLT-R           | −0.02      | 0.11  | 33.10 | −0.15 | 0.88  |
|  | Treatment x Time | 0.07       | 0.05  | 17.06 | 1.33  | 0.20  |
|  | Treatment x HVLT-R | −0.17    | 0.11  | 33.10 | −1.55 | 0.13  |
|  | Time x HVLT-R    | −0.03      | 0.08  | 19.61 | −0.49 | 0.63  |
|  | Treatment x Time x HVLT-R | −0.08 | 0.08 | 19.61 | 0.99 | 0.32  |
|  | **SDR composite** |          |       |       |       |       |
|  | Intercept        | 0.59       | 0.11  | 17.10 | 5.57  | <0.001*** |
|  | Treatment        | −0.10      | 0.11  | 17.10 | −0.92 | 0.37  |
|  | Time             | **0.17**   | **0.05** | **17.70** | **3.70** | **<0.001***** |
|  | SDR              | <0.01      | 0.12  | 29.05 | −0.07 | 0.92  |
|  | Treatment x Time | **0.10**   | **0.04** | **17.70** | **2.15** | **0.045*** |
|  | Treatment x SDR  | −0.07      | 0.12  | 29.05 | −0.68 | 0.50  |
|  | Time x SDR       | **0.23**   | **0.08** | **18.40** | **2.84** | **0.01*** |
|  | Treatment x Time x SDR | −0.16 | 0.08 | 18.40 | −1.97 | 0.06  |
|  | CPT hit rate     |           |       |       |       |       |
|  | Intercept        | 1.22       | 0.75  | 29.73 | 1.63  | 0.11  |
|  | Treatment        | −0.82      | 0.75  | 29.73 | −1.10 | 0.28  |
|  | Time             | −0.62      | 0.46  | 20.03 | −1.32 | 0.19  |
|  | CPT              | <−0.01     | <0.01 | 29.05 | −0.81 | 0.42  |
|  | Treatment x Time | 0.13       | 0.46  | 20.03 | 0.27  | 0.78  |
|  | Treatment x CPT  | <0.01      | <0.01 | 29.05 | 0.98  | 0.33  |
|  | Time x CPT       | <0.01      | <0.01 | 29.05 | 1.66  | 0.10  |
|  | Treatment x Time x CPT | <0.01 | <0.01 | 29.05 | 0.85  |
|  | CPT attentional index |           |       |       |       |       |
|  | Intercept        | 0.64       | 0.08  | 19.74 | 7.84  | <0.001*** |
|  | Treatment        | −0.09      | 0.08  | 19.74 | −1.16 | 0.8126 |
|  | Time             | **0.18**   | **0.06** | **18.43** | **3.01** | **0.007**** |
|  | CPT              | **0.12**   | **0.05** | **27.15** | **2.62** | **0.01*** |
|  | Treatment x Time | 0.07       | 0.06  | 27.15 | 1.26  | 0.22  |
|  | Treatment x CPT  | <0.01      | <0.01 | 27.15 | −2.82 | 0.009** |
|  | Time x CPT       | 0.01       | 0.04  | 22.52 | 0.15  | 0.88  |
|  | Treatment x Time x CPT | <0.01 | <0.01 | 22.52 | 0.61  |
|  | Intercept        | −0.03      | 0.16  | 14.72 | −0.19 | 0.029* |
|  | **TOL total correct** |       |       |       |       |       |
|  | Treatment        | **−0.64**  | **0.16** | **14.72** | **−4.12** | **<0.001***** |
|  | Time             | **0.35**   | **0.07** | **8.0**   | **4.52** | **0.05*** |
|  | TOL              | <0.001     | <0.001 | 8.19    | 2.87  | 0.01  |
|  | Treatment x Time | −0.30      | 0.07  | 8.02   | −3.84 | <0.001*** |
|  | Treatment x TOL  | <−0.01     | <0.001 | 8.19   | 5.75  | <0.001*** |
|  | Time x TOL       | <−0.01     | <0.001 | 8.05   | 2.31  | <0.05* |
|  | Treatment x Time x TOL | <0.01 | <0.001 | 8.05 | 5.29 | <0.001*** |
|  | **TOL total moves** |       |       |       |       |       |
|  | Intercept        | −0.13      | 0.35  | 11.80 | −0.36 | 0.72  |
|  | Treatment        | 0.26       | 0.35  | 11.80 | −0.75 | 0.47  |
|  | Time             | 0.01       | 0.17  | 7.29  | 0.08  | 0.94  |
|  | TOL              | <0.01      | <0.01 | 10.85 | 1.43  | 0.18  |
|  | Treatment x Time | −0.51      | 0.17  | 7.29  | −3.02 | 0.01** |
|  | Treatment x TOL  | <−0.01     | <0.001 | 7.29 | 1.08  | 0.30  |
|  | Time x TOL       | <0.01      | <0.01 | 7.32  | 0.96  | 0.36  |
|  | Treatment x Time x TOL | <0.01 | <0.01 | 7.32 | 3.79 | <0.006** |
|  | **TOL problem solving time** |       |       |       |       |       |
|  | Intercept        | −1.12      | 0.75  | 15.96 | 1.49  | 0.15  |
|  | Treatment        | −0.23      | 0.75  | 15.96 | −0.30 | 0.77  |
|  | Time             | −0.45      | 0.49  | 9.03  | −0.92 | 0.38  |
|  | TOL              | 0.02       | 0.08  | 15.96 | 1.97  | 0.06  |
DISCUSSION

The literature suggests overlapping neuropathophysiology between CUD and SCZ, as well as intersecting neurobiology associated with deficits in executive functioning experienced in both disorders (i.e., dysfunctional DLPFC24,25). Despite the high prevalence of CUD in SCZ, there remains a lack of consensus on potential treatments for this comorbidity. Thus, we investigated the role of neurocognitive performance on rTMS-induced changes in cannabis use. As expected, better baseline complex planning and delayed discounting abilities in SCZ predicted greater rTMS-induced changes in cannabis use over time, as measured by self-reported cannabis use and urinary THC-COOH. However, changes in neurocognitive performance did not mediate the efficacy of rTMS on changes in cannabis use. It is possible that substantial improvements in cognitive performance as a result of rTMS may require longer treatment periods to have a significant influence on cannabis use17.

Taken together, higher response inhibition (CPT hit rate), complex planning accuracy, and delayed discounting all predicted reduced cannabis use in the active rTMS group. Although complex planning efficiency was negatively correlated to reduced GPD in the active group (e.g., participants who took longer to plan moves experienced greater improvements), other research has found that in healthy samples, longer planning times predicted a greater number of “perfect solutions”26 and as such may not reflect a deficit in complex planning. Similarly, participants in this sample who took longer to solve the problem were also more likely to have greater accuracy on the TOL. Significant moderation effects observed in the active rTMS group suggest select baseline cognitive abilities might have influenced the extent to which rTMS reduces cannabis use, either directly or indirectly through encouraging engagement in behavioral treatment sessions. Poorer delayed discounting, response inhibition, and complex planning skills may reflect a more severe SCZ profile that influences the degree to which rTMS is effective through how much an individual is able or willing to participate in recovery, inhibit impulses to use drugs, and maintain long-term goals. Thus, integrating supportive therapies that help individuals overcome cognitive deficits (e.g., cognitive remediation strategies27) may facilitate the effects of neuromodulation on CUD outcomes in SCZ.

Notably, in the sham group some participants reduced cannabis use with the help of weekly behavioral support sessions; our moderation analyses suggest that this primarily relied on better select baseline cognitive functions. Conversely in the active group, improvements were seen regardless, albeit to varying extents dependent on delayed discounting, response inhibition, and complex planning skills (Supplementary Figure). This indicates rTMS may act independently of some aspects of cognitive performance to reduce cannabis use in SCZ. Executive dysfunction in SCZ traditionally represents a significant hindrance to complex behaviors such as addiction recovery as they are associated with greater risk-taking, more impulsivity, difficulty setting and maintaining goals, and poor cognitive flexibility12,28. Delayed discounting, complex planning, and response inhibition may have a moderating effect on rTMS effects that is not observed from other cognitive tasks, due to their close relation to substance use behaviors (e.g., making choices now to abstain for greater future goals like recovery, over choosing immediate reward like the high from the substance, “urge surfing” cravings), as well as creating and following recovery plans12. Furthermore, although studies have found better baseline verbal learning and memory, working memory, and attention to predict greater success in recovery14, these skills may have been more amenable to rTMS and thus baseline performance was not predictive of changes in cannabis use. Indeed, our mediation models found medium treatment effects on the HVLT-R and CPT attentional index, potentially indicating treatment-associated compensation
for these skills in reducing cannabis use. It is also possible that these tests were less sensitive in assessing target domains. However, we recognize that this study has a small sample size and hope to replicate these findings in a larger sample. Nonetheless, we believe this is relevant to the scientific community for directing future studies.

While the indirect effect of neuropsychological changes predicting changes in cannabis use was not significant, we were underpowered for mediation analysis, and it was an exploratory undertaking to see potential paths that explain individual differences in cannabis use outcomes after rTMS treatment related to neuropsychological underpinnings of SCZ. Future research should assess the extent to which neuropsychological changes influence rTMS effects on cannabis use, given findings that baseline performance significantly affects the degree to which rTMS is effective in reducing cannabis use.

Nonetheless, there were several notable findings pertinent to the model of change hypothesis. There was a medium effect of

Fig. 1 Models of change neurocognitive mediation plot. Models of change figure depicting standardized effect sizes along with standard error of the mean estimates for indirect pathways through select neurocognitive functions as a mediator between rTMS treatment and changes in cannabis use.
active treatment on improvements in sustained attention, complex planning, as well as verbal learning and memory, supporting previous research showing cognitive improvements in SCZ after rTMS treatment. In SCZ, reduced cortical activity results in a lack of cortical inhibitory control, impairing suppression of hyperactive automatic tendencies that maintain addiction. Given dysfunctional frontal-subcortical circuitry in SCZ, co-occurring CUD worsens cognitive impairment, further hindering recovery attempts. That is, overstimulation of widespread dysregulated CB1Rs leads to aberrant neurotransmission, such as blunted dopaminergic activity in subcortical regions and cognitive decline, making it difficult to sustain long-term goals like abstinence. Encouragingly, the application of rTMS to the DLPFC facilitates the induction of temporary electric currents and normalizes cortical excitability in this region. Normalization of activity in the DLPFC may lead to enhanced cognitive control, reducing cannabis use behavior. Furthermore, changes in sustained attention and complex planning had a medium effect on reductions in cannabis use. These skills may facilitate engagement with supportive behavioral interventions delivered alongside rTMS, potentially amplifying benefits of behavioral interventions. Secondary outcomes of normalized activity in reward processing centers and pathways may further reduce cannabis use in combination with influences from behavioral support. Indeed, we also found small to medium effects of changes of verbal working memory, and complex planning on changes in cannabis use. Hypothesized improvements in cognitive functioning related to rTMS in SCZ and relations to engagement in behavioral interventions may be established by comparing rTMS responses with and without the behavioural counselling intervention.

**Limitations**

The main limitation of this study is the small sample size. Indeed, the study was underpowered and results should be considered preliminary; results should be replicated in a larger sample size for generalizability of findings. Individuals with SCZ exhibit reduced motivation in quitting or reducing cannabis use and experience paranoia about new treatments as well as accessibility issues with attending in-person sessions, such that a multi-site trial may enhance recruitment efforts. Moreover, we did not correct for multiple comparisons for the various neuropsychological analyses conducted as our analyses were exploratory. Notably, previous studies in people with schizophrenia have found no cannabis-abstinence induced improvements in Digit Span, CPT, SDR, or the KDDT, suggesting any improvements in this sample to be a direct result of rTMS. However, it is still possible that changes in rTMS-induced changes in cannabis use may have resulted in changes in select cognitive functions (e.g., HVLT) or the TOL. The direction of change is not conclusive without a larger sample or comparison of neurocognitive functions that reduce cannabis use in response to active (versus sham) rTMS treatment, relative to those who do not. Furthermore, it is possible practice effects played a role in changes in neurocognitive performance from baseline to end of treatment; however, please note that a training session that was not analyzed was used prior to baseline to reduce the presence of practice effects. In addition, use of brain-based measurements

---

**Table 3. Sample baseline demographic and clinical characteristics.**

| Measure                              | Group          | p   |
|--------------------------------------|----------------|-----|
|                                      | Active rTMS (n = 9) | Sham (n = 10) |
| Diagnosis (SCZ/SA)                   | 7/2            | 7/3 | ns |
| Age of SCZ diagnosis (years)         | 23.89 ± 4.70   | 20.40 ± 2.07 | 0.05 |
| Atypical/typical/both AP             | 6/0/3          | 8/2/0 | ns |
| Age (years)                          | 34.78 ± 10.35  | 29.10 ± 5.38 | 0.15 |
| Gender (M/F)                         | 9/0            | 9/1 | ns |
| Ethnicity (White/Black/Hispanic/Other/Mixed) | 5/3/1/0/0      | 4/3/0/1/2 | ns |
| Education (years)                    | 12.56 ± 2.60   | 12.35 ± 1.63 | 0.24 |
| WTAR IQ Score                        | 105.89 ± 9.25  | 105.20 ± 5.96 | 0.85 |
| PANSS total                          | 54.44 ± 10.01  | 54.90 ± 8.25 | 0.29 |
| PANSS general                        | 26.00 ± 5.70   | 24.10 ± 5.02 | 0.45 |
| PANSS negative                       | 14.67 ± 4.61   | 13.60 ± 3.60 | 0.58 |
| PANSS positive                       | 13.78 ± 3.42   | 12.20 ± 3.58 | 0.34 |
| WTAR IQ Score                        | 105.89 ± 9.25  | 105.20 ± 5.96 | 0.85 |
| PANSS general                        | 54.44 ± 10.01  | 54.90 ± 8.25 | 0.29 |
| PANSS total                          | 26.00 ± 5.70   | 24.10 ± 5.02 | 0.45 |
| PANSS negative                       | 14.67 ± 4.61   | 13.60 ± 3.60 | 0.58 |
| PANSS positive                       | 13.78 ± 3.42   | 12.20 ± 3.58 | 0.34 |
| PANSS severity (moderate/severe)     | 4/5            | 4/6 | ns |
| Grams per day                        | 0.64 ± 0.27    | 1.32 ± 1.94 | 0.31 |
| NarcoCheck® THC-COOH (ng/mL)         | 385.53 ± 222.62| 360.00 ± 214.48 | 0.80 |
| CUDIT-R (n = 6,6)                    | 16.17 ± 6.97   | 17.83 ± 5.12 | 0.65 |
| Joint-Years                          | 10.37 ± 7.83   | 6.59 ± 4.66 | 0.21 |
| Age of first cannabis use            | 16.33 ± 2.78   | 15.90 ± 2.28 | 0.71 |
| Age of first regular cannabis use    | 19.33 ± 2.96   | 17.20 ± 2.66 | 0.12 |
| Previous quit attempts               | 1.67 ± 1.41    | 2.40 ± 3.89 | 0.60 |
| AUDIT (n = 5,6)                      | 3.60 ± 2.41    | 4.00 ± 2.37 | 0.79 |
| FTND                                 | 2.56 ± 1.94    | 3.90 ± 3.28 | 0.30 |
| Carbon monoxide level (ppm)          | 11.56 ± 9.58   | 18.10 ± 13.30 | 0.24 |

**Neurocognitive Tasks median (range)**

| Hopkins Verbal Learning Test         |               |     |
|--------------------------------------|----------------|-----|
| Delayed recall                       | 8 (2–10)       | 7 (4–12) | 0.71 |
| Percent retention                    | 88.9 (50–133)  | 87.5 (54.5–116.7) | 0.65 |
| Discrimination index                 | 10 (4–12)      | 11 (6–12) | 0.14 |
| Spatial delayed response             |               |     |
| 5 s delay                            | 19 (8–38)      | 21 (13–48) | 0.81 |
| 15 s delay                           | 19 (10–62.3)   | 22.5 (16.4–68) | 0.72 |
| 30 s delay                           | 25 (10–80)     | 25 (19.6–83) | 0.49 |
| Digit Span task                      |               |     |
| Forward                              | 10 (7–16)      | 10 (4–13) | 0.87 |
| Backward                             | 7 (4–10)       | 6 (3–9) | 0.65 |

**Continuous Performance Test**

| Variability                          | 13.26 (3.18–33.52)| 17.57 (4.36–53.05) | 0.84 |
| Hit rate                             | 407.47 (345.66–520.63) | 372.12 (310.4–431.88) | 0.08 |
| Attentional index (d')               | 1.52 (–2.48–4.27) | 0.56 (–3.46–0.93) | 0.08 |

**Kirby Delay-Discounting Task**

| Natural logarithm of Geometric K     | –3.67 (–4.19––3.06) | –2.90 (–6.44–1.62) | 0.36 |
| Tower of London                      | 82 (78–132)         | 88 (80–98) | 0.56 |
| Problem solving time                 | 100 (92–104)        | 95 (76–100) | 0.88 |

**Table 3 continued**

| Measure                              | Group          | p   |
|--------------------------------------|----------------|-----|
|                                      | Active rTMS (n = 9) | Sham (n = 10) |
| Total moves                          | 87 (78–118)    | 87 (70–96) | 0.38 |
| Initiation                           | 99 (92–102)    | 99 (96–110) | 0.88 |

...
(e.g., positron emission topography, magnetic resonance imaging, electroencephalogram) may be informative to understanding neurobiological changes occurring as a result of rTMS and whether these are associated with changes in neurocognitive functions and cannabis use. Finally, there was a significant effect of time in both groups, potentially indicative of regression to the mean, or a result of cannabis behavioral sessions received by both groups. Nonetheless, differences between treatment groups support efficacy of rTMS for treating CUD in individuals with SCZ as well as the relevance of neurocognitive functioning to treatment outcomes.

CONCLUSIONS

We found significant moderating effects of baseline delayed discounting, response inhibition, and complex planning that may explain the effects of high-frequency rTMS on cannabis use outcomes in SCZ. However, mediation of cannabis use outcomes by rTMS-related improvements in cognition was not significant. Our findings support the importance of cognitive deficits in understanding rTMS effects on cannabis use in SCZ. Further research with larger samples is needed to determine whether rTMS-related changes in cognitive functioning in SCZ may influence cannabis use outcomes in a clinically significant manner.

METHODS

Participants

We recruited 19 individuals (18–55 years) diagnosed with SCZ or schizoaffective disorder and co-occurring CUD with the Structured Clinical Interview for the DSM-5; CUD severity was ascertained using the Cannabis Use Disorder Identification Test-Revised (CUDIT-R). We required participants to have a positive urine drug test for THC-COOH on MEDTOX®, and NarcoCheck® semi-quantitative levels ≥150 ng/ml at baseline to indicate current cannabis use (see ref. 19). Exclusion criteria were other substance use (other than caffeine, non-disordered alcohol use, or nicotine), suicidal ideation, a history of seizures, or previous rTMS treatment (CONSORT diagram can be found in ref. 19). Sample demographics and clinical characteristics are reported in Table 3. Cannabis Timeline Follow-back and NarcoCheck® were administered weekly to assess changes in self-reported cannabis GPD and in semi-quantitative THC-COOH content present in urine, respectively 19. All participants gave written informed consent, as per the Centre for Addiction and Mental Health Research Ethics Board.

Participants in the active group received high-frequency (20 Hz) repetitive rTMS applied to bilateral dorsolateral prefrontal cortex 5x/week for 4 weeks. All participants regardless of rTMS treatment condition received weekly behavioral support sessions motivating abstinence from cannabis use (further details in ref. 19).

Neurocognitive tasks

Participants completed the Hopkins Verbal Learning Test (HVLT-R) to assess verbal learning and memory, Spatial Delayed Response task (SDR) to assess delayed visuospatial working memory, the Digit Span (DS) task to assess verbal working memory, the Kirby Delay-Discounting Task (KDDT) to assess delayed discounting and impulsivity, the Continuous Performance Test (CPT) to assess sustained attention, and the Tower of London (TOL) to assess complex planning and problem solving. Specific outcomes assessed and participant scores are reported in Table 1; further details on tasks can be found in ref. 19. Note that for the KDDT, Geometric K scores are reported, which describe an individual’s subjective value of delayed rewards, such that larger K values represent steeper discounting of rewards even with small time delays49. All participants completed a cognitive training session prior to baseline to reduce practice effects that may emerge between baseline and end of treatment41.

Statistical analysis

Statistical analyses were conducted using Statistical Program for Social Sciences (SPSS®) and R v.4.1.2 (R Core Team, 2021). Demographic and baseline measures for active and sham groups were compared using independent t-tests and chi-square tests. Main treatment effects on clinical and cognitive symptoms are reported elsewhere19. Outliers on neurocognitive tasks flagged by boxplot analysis as being three standard deviations above the mean were removed.

To reduce the number of analyses, composite scores were created for HVLT-R outcomes (delayed recall, retention, discrimination index) and SDR outcomes (5 s, 15 s, 30 s delays) by converting raw scores for each outcome to z scores and averaging across all included outcomes. These individual outcomes are conceptually and statistically related and have previously been combined as composites in the literature32,43. Remaining outcomes were assessed independently.

Random intercept linear mixed-effects models fit with maximum likelihood using R packages lmer and afex were used to determine interaction effects of time x treatment condition x baseline neuropsychological performance (as a continuous measure) on changes in cannabis GPD and reductions in THC content in urine from baseline to Day 28 (described above). Significance levels were determined with Satterthwaite’s method and estimated marginal means (tukey corrected) in R package emmeans were used to conduct post hoc analyses. Mixed model function in lmer package outputs a t-distributed statistic and degrees of freedom that was then converted to Cohen’s d effect size. Results are reported as effect sizes with 95% confidence intervals; significant findings do not contain the null hypothesis value(0). Note that there was a significant difference between groups with respect to age of schizophrenia diagnosis, but this was not related to cannabis or neurocognitive outcomes and thus removed from models for better fit.

With respect to models of change, mediation analyses were conducted using PROCESS44 to explore the mediating effect of executive functioning tasks hypothesized to change as a result of non-invasive neuromodulation. Specifically, these were the HVLT-R (percent retention and discrimination index), SDR 30 s delay, CPT (Hit Rate, Variability, Attentiveness), Digit Span (Forward and Backward) and TOL14,19,45–47. Given the exploratory nature of this analysis, the dearth of available clinical literature in this area, and the goal of assessing specificity of rTMS treatment effects on neurocognitive performance, composite scores for HVLT-R and SDR were not used. Change scores were calculated by subtracting baseline scores from end of treatment scores; change scores, treatment, and changes in GPD, were then converted to z-scores to obtain completely standardized coefficients. PROCESS uses bootstrapping to output the direct effect, which in this case is the relationship between the rTMS treatment (active) and changes in cannabis use (baseline to day 28), controlling for the specific mediator; the indirect effect (AB), which assesses whether changes in neuropsychological performance (baseline to day 28, pathway A) mediates the relationship between active rTMS and changes in cannabis use (pathway B); and the total effect that sums the direct and indirect effects. Only complete cases were used. The mediation analyses was an exploratory objective for which our study has low power48 hence, mediational effects are presented and interpreted in a general way, with focus on estimated effect and their precision, rather than their statistical significance.
DATA AVAILABILITY
The data supporting the findings of this study are not publicly available due to ethical restrictions for protecting participants’ confidentiality and privacy but are accessible from the corresponding author on reasonable request with the approval of the Institutional Review Board of CAMH.

CODE AVAILABILITY
No custom code or mathematical algorithm was used for this study.

Received: 25 July 2022; Accepted: 20 October 2022;
Published online: 17 November 2022

REFERENCES
1. Orellana, G. & Slachsevsky, A. Executive functioning in schizophrenia. Front. Psychiatry 4, 35 (2013).
2. Hunt, G. E., Large, M. M., Cleary, M., Lai, H. M. K. & Saunders, J. B. Prevalence of comorbid substance use in schizophrenia spectrum disorders in community and clinical settings, 1990–2017: Systematic review and meta-analysis. Drug Alcohol Depend. 191, 234–258 (2018).
3. D’Souza, D. C. et al. Consensus paper of the WFSBP task force on cannabis, cannabinoids and psychosis. World J. Biol. Psychiatry 22, 1–24 (2022).
4. Johansen, R. et al. Cognitive and clinical factors are associated with service engagement in early-phase schizophrenia spectrum disorders. J. Nervous Ment. Dis. 199, 175–183 (2011).
5. El-Missiry, A. et al. Comparing cognitive functioning in medication adherent and non-adherent patients with schizophrenia. J. Psychiatriatr. Res. 70, 106–112 (2015).
6. Duff, K., Schoonberg, M., Scott, J. & Adams, R. The relationship between executive functioning and verbal and visual learning and memory. Arch. Clin. Neuropsychol. 20, 111–122 (2005).
7. Blume, A. W., Davis, I. M. & Schmaling, K. B. Neurocognitive dysfunction in dually-diagnosed patients: a potential roadblock to motivating behavior change. J. Psychoactive Drugs 31, 111–115 (1999).
8. Rinn, W., Desai, N., Rosenblatt, H. & Gastfriend, D. R. Addiction denial and cognitive dysfunction: a preliminary investigation. J. Neuropsychiatry Clin. Neurosci. 14, 52–57 (2002).
9. Rubenison, A. J., Fitzpatrick, R. E., Lubman, D. I. & Verdejo-Garcia, A. Sustained attention but not effort-based decision-making predicts treatment motivation change in people with methamphetamine dependence. J. Subst. Abuse Treat. 95, 48–54 (2018).
10. Morgenstern, J. & Bates, M. E. Effects of executive function impairment on change processes and substance use outcomes in 12-step treatment. J. Stud. Alcohol. 60, 846–855 (1999).
11. Bates, M. E., Pawlak, A. P., Tonigan, J. S. & Buckman, J. F. Cognitive impairment influences drinking outcome by altering therapeutic mechanisms of change. Psychol. Addit. Behav. 20, 241–253 (2006).
12. Fishbein, D. et al. Neurocognitive skills moderate urban male adolescents’ responses to preventive intervention materials. Drug Alcohol Depend. 82, 47–60 (2006).
13. Loughead, J. et al. Working memory-related neural activity predicts future smoking relapse. Neuropsychopharmacology. 40, 1311–1320 (2015).
14. Moss, T. G. et al. Prefrontal cognitive dysfunction is associated with tobacco dependence treatment failure in smokers with schizophrenia. Drug Alcohol Depend. 104, 94–99 (2009).
15. Rabin, R. A., Goodman, M. S., George, T. P. & Barr, M. S. Neurobiology of comorbid substance use disorders in mental illness: a closer look at the underlying commonalities between cannabis and schizophrenia. Curr. Addict. Rep. 1, 261–271 (2014).
16. Beylerleng, S. B. et al. Dorsolateral prefrontal cortex contributes to the impaired behavioral adaptation in alcohol dependence. Neuroimage: Clin. 15, 80–94 (2017).
17. Johnstone, S. et al. Neurormodulation to treat substance use disorders in people with schizophrenia and other psychoses: a systematic review. Front. Psychiatry. 13 1–11 (2022).
18. Kozak, K., Barr, M. S. & George, T. P. Traits and biomarkers for addiction risk in schizophrenia. Curr. Addict. Rep. 4, 14–24 (2017).
19. Kozak-Bidzinski, K. et al. Investigating repetitive transcranial magnetic stimulation on cannabis use and cognition in people with schizophrenia. Schizophrenia 8, 2 (2022).
20. Coles, A. S., Kozak, K. & George, T. P. A review of brain stimulation treatments to treat substance use disorders. Am. J. Addict. 27, 71–91 (2018).
21. Moretti, J., Poh, E. Z. & Rodger, J. rTMS-induced changes in glutamatergic and dopaminergic systems: relevance to cocaine and methamphetamine use disorders. Front. Neurosci. 14, 137 (2020).

ACKNOWLEDGEMENTS
We thank Alexandria Coles, Julia Sasiadek, and Emily Simkin, RN for their assistance with the procedures used in this study. This study was supported by a CIHR Pre-
Doctoral Fellowship (to Dr. Kozak Bidzinski) and NIDA grant R21-DA-043949 (to Dr. George).

AUTHOR CONTRIBUTIONS
S.J.: Writing—original draft, formal analysis, visualization; D.J.E.L.: Writing—original draft, formal analysis, visualization, investigation; K.K.B.: investigation, funding acquisition; M.S.: Writing—review and editing, formal analysis, software; J.R.: Writing—review and editing; R.A.R.: Writing—review and editing; D.J.C.: Writing—review and editing; T.P.G.: Writing—review and editing, supervision, investigation, funding acquisition, project administration. All authors approved the final version of the manuscript.

COMPETING INTERESTS
Dr. George declares that in the past three years, he has been a consultant to Frutarom, Aelis, Sanford Burnham Prebys Discovery, Novartis and the Canadian Centre for Substance Use and Addiction, and Deputy Editor for the journal Neuropsychopharmacology. All other authors have no competing interest to declare.

ADDITIONAL INFORMATION
Supplementary information The online version contains supplementary material available at https://doi.org/10.1038/s41537-022-00303-2.

Correspondence and requests for materials should be addressed to Tony P. George.

Reprints and permission information is available at http://www.nature.com/reprints

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

© The Author(s) 2022